The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Mar 21, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how social isolation and social interaction affect the risk of dementia progression and brain function in individuals experiencing subjective cognitive decline (SCD). Researchers want to understand if feeling lonely can lead to more significant cognitive issues, such as mild cognitive impairment (MCI) or Alzheimer’s disease (AD), and whether social interactions can help protect against these changes. They will study different groups of people, explore brain function in relation to genetics, and develop models to predict cognitive decline based on social factors.

To participate, individuals must be between 45 and 85 years old, have noticeable cognitive decline without any acute causes, and can provide consent. Participants will undergo various assessments, including cognitive tests, to help researchers gather valuable information. The trial is currently recruiting participants and aims to offer insights that could lead to personalized support for those experiencing SCD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • SCD
• • 1. Self-perceived continuous cognitive decline compared with the previous normal state, and is not related to acute events;
• • 2. After adjustment for age, gender, and years of education, the standard cognitive test is normal, or the diagnostic criteria for MCI are not met;
• • 3. Selected candidates can sign the informed consent form themselves.
• Exclusion Criteria:
• • (a) Aged under 45 years or older than 85 years; (b) Vascular dementia or other central nervous system diseases; (c) Hachinski Ischemic Scale score \> 4 points; (d); Unable to complete neuropsychological tests (e.g., blindness, deafness, severe language impairment); (e) Drug abuse or alcohol dependency within the last 6 months; (f) Current participation in other cognition studies; (g) Severe diabetes mellitus, or severe cardiovascular disease, cerebrovascular disease, liver diseases, kidney diseases, psychiatric disorders; (h) Contraindications to imaging techniques: claustrophobia, metallic implants (e.g., intracranial metal clips), electronic devices (e.g., cardiac pacemakers)